Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Prior, Celia ^a   Perez Gracia, Jose Luis ^b   Garcia Donas, Jesus ^c   Rodriguez Antona, Cristina ^d   Guruceaga, Elizabeth ^a   Esteban, Emilio ^e   Suarez, Cristina ^f   Castellano, Daniel ^g   Del Alba, Aránzazu González ^h   Lozano, Maria Dolores ^b   Carles, Joan ^f   Climent, Miguel Angel ⁱ   Arranz, Jose Angel ^j   Gallardo, Enrique ^k   Puente, Javier ^l   Bellmunt, Joaquim ^m   Gurpide, Alfonso ^b   Lopez Picazo, Jose Maria ^b   Hernandez, Alvaro Gonzalez ^b   Mellado, Begoña ⁿ   Martínez, Esther ^o   Moreno, Fernando ^l   Font, Albert ^p   Calvo, Alfonso ^a   more..

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL DE SABADELL   (Spain)

^l HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^m HOSPITAL DEL MAR   (Spain)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o Hosp Univ Ciudad de Jaén   (Spain)

^p HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MICRORNA; MICRORNA 133A; MICRORNA 484; MICRORNA 628 5P; MICRORNA 942; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MIDDLE AGED; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MICRORNAS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PARACRINE COMMUNICATION; PROGNOSIS; PYRROLES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898478153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086263     Document Type: Article

References (34)

1. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. The Lancet Oncology 13: e249-e258.
2. Gamez-Pozo A, Anton-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, et al. (2012) MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 14: 1144-1152.
3. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, et al. (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12: 1143-1150.
4. Perez-Gracia JL, Gloria Ruiz-Ilundain M, Garcia-Ribas I, Maria Carrasco E (2002) The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research. Cancer 95: 1605-1610.
5. Nebert DW (2000) Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 410: 107-120.
6. Zhang G, Nebert DW, Chakraborty R, Jin L (2006) Statistical power of association using the extreme discordant phenotype design. Pharmacogenet Genomics 16: 401-413. (Pubitemid 43804798)
7. Perez-Gracia JL, Gurpide A, Ruiz-Ilundain MG, Alfaro Alegria C, Colomer R, et al. (2010) Selection of extreme phenotypes: the role of clinical observation in translational research. Clin Transl Oncol 12: 174-180.
8. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, et al. (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28: 4674-4682.
9. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, et al. (2011) HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29: 667-673.
10. Perez-Gracia JL, Prior C, Guillen-Grima F, Segura V, Gonzalez A, et al. (2009) Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 101: 1876-1883.
11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124. (Pubitemid 46089672)
12. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
13. Lall S, Grun D, Krek A, Chen K, Wang YL, et al. (2006) A genome-wide map of conserved microRNA targets in C. elegans. Curr Biol 16: 460-471. (Pubitemid 43343706)
14. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39: 1278-1284. (Pubitemid 47482690)
15. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-153. (Pubitemid 351149712)
16. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-158. (Pubitemid 351149713)
17. Gentleman R CV, Dudoit S, Irizarry RA, Huber W (2005) Bioinformatics and computational biology solutions using R and Bioconductor. Springer.
18. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
19. Bellmunt J, Gonzalez-Larriba JL, Prior C, Maroto P, Carles J, et al. (2011) Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 22: 2646-2653.
20. Zhou L, Chen J, Li Z, Li X, Hu X, et al. (2010) Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One 5: e15224.
21. Powers MP, Alvarez K, Kim HJ, Monzon FA (2011) Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping. Diagn Mol Pathol 20: 63-70.
22. Youssef YM, White NM, Grigull J, Krizova A, Samy C, et al. (2011) Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59: 721-730.
23. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, et al. (2010) Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 29: 90.
24. Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, et al. (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29: 367-373.
25. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, et al. (2010) Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 31: 1805-1812.
26. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447.
27. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, et al. (2011) The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 18: 85-95.
28. Catena R, Luis-Ravelo D, Anton I, Zandueta C, Salazar-Colocho P, et al. (2011) PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Cancer Res 71: 164-174.
29. McCawley LJ, Matrisian LM (2001) Tumor progression: defining the soil round the tumor seed. Curr Biol 11: R25-27. (Pubitemid 32062705)
30. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
31. Jadhav U, Chigurupati S, Lakka SS, Mohanam S (2004) Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol 25: 1407-1414.
32. D'Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3: 23-34. (Pubitemid 37328884)
33. Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, et al. (2008) Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci 99: 553-563.
34. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, et al. (2005) Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 76: 168-176. (Pubitemid 41725444)